The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Vancomycin: A History
Abstract
Vancomycin became available for clinical use >50 years ago but was soon discarded in favor of other antibiotics that were deemed to be more efficacious and less toxic. The advent of pseudomembranous enterocolitis, coupled with the spread of methicillin-resistant Staphylococcus aureus, led to a resurgence in the use of vancomycin. Almost immediately, concerns arose with regard to its therapeutic utility. In addition, resistance to vancomycin developed, first in enterococci and later in staphylococci. Several types of resistance have now been identified, each with a unique effect on infections treated with vancomycin. Recent studies have rekindled interest in the best way to administer the antibiotic. The findings of future studies may result in a return to measuring levels of vancomycin in serum, to assure a successful therapeutic outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Vancomycin-Resistant Enterococci
Cetinkaya, Y., Falk, P., & Mayhall, C. G. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.4.686 · Cited by 1,163
Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095
Vancomycin-Resistant Enterococcal Infections
Murray, B. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421007 · Cited by 890
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
Self-citationHowden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981
Farber, B. F., & Moellering, R. C. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.1.138 · Cited by 432
Gonzalez, C., Rubio, M., Romero-Vivas, J., Gonzalez, M., & Picazo, J. J. (1999) · Clinical Infectious Diseases · doi:10.1086/313440 · Cited by 407
Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
Small, P. M., & Chambers, H. F. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1227 · Cited by 399
STAPHYLOCOCCUS AUREUS RESISTANT TO VANCOMYCIN???UNITED STATES, 2002
&NA; (2002) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200203000-00016 · Cited by 395
Methicillin-Resistant Staphylococcus aureus: Introduction and Spread Within a Hospital
PEACOCK, J. E., MARSIK, F. J., & WENZEL, R. P. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-526 · Cited by 391
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Nephrotoxicity of vancomycin, alone and with an aminoglycoside
Rybak, M. J., Albrecht, L. M., Boike, S. C., & Chandrasekar, P. H. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.4.679 · Cited by 388
Charles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P., & Grayson, M. L. (2004) · Clinical Infectious Diseases · doi:10.1086/381093 · Cited by 384
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.4.1020-1027.1998 · Cited by 376
Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania
Tenover, F. C., Weigel, L. M., Appelbaum, P. C., McDougal, L. K., Chaitram, J., McAllister, S., Clark, N., Killgore, G., O'Hara, C. M., Jevitt, L., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.275-280.2004 · Cited by 370
Pharmacokinetics of vancomycin in patients with various degrees of renal function
Matzke, G. R., McGory, R. W., Halstenson, C. E., & Keane, W. F. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.4.433 · Cited by 362
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., McAllister, S. K., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2167-2167.1998 · Cited by 362
KORZENIOWSKI, O., & SANDE, M. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-4-496 · Cited by 355
SARAVOLATZ, L. D., MARKOWITZ, N., ARKING, L., POHLOD, D., & FISHER, E. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-1-11 · Cited by 355
Diagnosis and Treatment of Clostridium difficile Colitis
Fekety, R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500010081036 · Cited by 354
Fowler, Jr., Sakoulas, G., McIntyre, L. M., Meka, V. G., Arbeit, R. D., Cabell, C. H., Stryjewski, M. E., Eliopoulos, G. M., Reller, L. B., Corey, G. R., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/423145 · Cited by 351
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344
Markowitz, N., Quinn, E. L., & Saravolatz, L. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-5-390 · Cited by 343
Moise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A., & Moellering, R. C. (2004) · Clinical Infectious Diseases · doi:10.1086/421092 · Cited by 332
Liu, C., & Chambers, H. F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3040-3045.2003 · Cited by 321
Weinstein, R. A., & Fridkin, S. K. (2001) · Clinical Infectious Diseases · doi:10.1086/317542 · Cited by 304
SARAVOLATZ, L. D., POHLOD, D. J., & ARKING, L. M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-325 · Cited by 290
Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage
MOELLERING, R. C., KROGSTAD, D. J., & GREENBLATT, D. J. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-3-343 · Cited by 278
Historical Yearly Usage of Vancomycin
Kirst, H. A., Thompson, D. G., & Nicas, T. I. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1303 · Cited by 276
Vancomycin-resistant Staphylococcus aureus
Howe, R. A., Bowker, K. E., Walsh, T. R., Feest, T. G., & MacGowan, A. P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78597-4 · Cited by 274
Penetration of vancomycin into human lung tissue
Cruciani, M., Gatti, G., Lazzarini, L., Furlan, G., Broccali, G., Malena, M., Franchini, C., & Concia, E. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.5.865 · Cited by 264
Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus
SORRELL, T. C., PACKHAM, D. R., SHANKER, S., FOLDES, M., & MUNRO, R. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-344 · Cited by 260
Production of l-DOPA by Aspergillus terreus
Chattopadhyay, S., & Das, A. (1990) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1990.tb03888.x · Cited by 243
Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value
Cantu, T. G., Yamanaka-Yuen, N. A., & Lietman, P. S. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.533 · Cited by 230
Sivagnanam, S., & Deleu, D. (2003) · Critical Care · doi:10.1186/cc1871 · Cited by 230
Vancomycin-Resistant Staphylococcus aureus--Pennsylvania, 2002
(2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.17.2116 · Cited by 228
LEVINE, D. P., CUSHING, R. D., JUI, J., & BROWN, W. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-330 · Cited by 224
Self-citationReduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996
(1997) · American Journal of Infection Control · doi:10.1016/s0196-6553(97)90087-0 · Cited by 224
Genetic Characterization of vanG , a Novel Vancomycin Resistance Locus of Enterococcus faecalis
McKessar, S. J., Berry, A. M., Bell, J. M., Turnidge, J. D., & Paton, J. C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.3224-3228.2000 · Cited by 210
Community-acquired methicillin-resistant Staphylococcus aureus infections
Maltezou, H. C., & Giamarellou, H. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.11.004 · Cited by 197
SOME LABORATORY AND CLINICAL EXPERIENCES WITH A NEW ANTIBIOTIC, VANCOMYCIN
Geraci, J. E., Heilman, F. R., Nichols, D. R., Wellman, W. E., & Ross, G. T. (1956) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(26)01926-9 · Cited by 184
Vancomycin-resistant Staphylococcus aureus--New York, 2004.
(2004) · PubMed · Cited by 181
The Role of Vancomycin in the Treatment Paradigm
Stevens, D. L. (2006) · Clinical Infectious Diseases · doi:10.1086/491714 · Cited by 172
Adaptation of Methicillin-Resistant Staphylococcus aureus in the Face of Vancomycin Therapy
Sakoulas, G., Moellering, R. C., & Eliopoulos, G. M. (2006) · Clinical Infectious Diseases · doi:10.1086/491713 · Cited by 165
Apisarnthanarak, A., Razavi, B., & Mundy, L. M. (2002) · Clinical Infectious Diseases · doi:10.1086/342334 · Cited by 161
The vanG glycopeptide resistance operon from Enterococcus faecalis revisited
Depardieu, F., Bonora, M. G., Reynolds, P. E., & Courvalin, P. M. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03737.x · Cited by 151
Moore, M. R., Perdreau‐Remington, F., & Chambers, H. F. “. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1262-1266.2003 · Cited by 149
RecurrentStaphylococcus aureusBacteremia: Pulsed‐Field Gel Electrophoresis Findings in 29 Patients
Fowler, V. G., Kong, L., Corey, G. R., Gottlieb, G. S., McClelland, R. S., Sexton, D. J., Gesty‐Palmer, D., & Harrell, L. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/314712 · Cited by 149
Vancomycin‐ResistantStaphylococcus aureusin the Absence of Vancomycin Exposure
Whitener, C., Park, S. Y., Browne, F. A., Parent, L. J., Julian, K. G., Bozdoğan, B., Appelbaum, P. C., Chaitram, J. M., Weigel, L. M., Jernigan, J. A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/382357 · Cited by 148
White, A. R. (2006) · Acupuncture in Medicine · doi:10.1136/aim.24.suppl.iii · Cited by 142
Antibiotic Therapy of Bacterial Endocarditis
GERACI, J. E., & Martin, W. J. (1953) · Circulation · doi:10.1161/01.cir.8.4.494 · Cited by 130
Cimino, M. A., Rotstein, C., Slaughter, R. L., & Emrich, L. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90947-8 · Cited by 128
Editorial: Monitoring Serum Vancomycin Levels: Climbing the Mountain Because It Is There?
Moellering, R. C. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.544 · Cited by 123
Gravet, A., Rondeau, M., Harf‐Monteil, C., Grünenberger, F., Monteil, H., Scheftel, J. M., & Prévost, G. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.12.4012-4019.1999 · Cited by 122
Gerding, D. N. (1997) · Clinical Infectious Diseases · doi:10.1086/516247 · Cited by 119
Vancomycin- and erythromycin-induced hearing loss in humans
Brummett, R. E., & Fox, K. E. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.6.791 · Cited by 119
Vancomycin Ototoxicity in a Patient with Normal Renal Function
Traber, P. G., & Levine, D. P. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-95-4-458 · Cited by 99
Self-citationHackbarth, C. J., Chambers, H. F. “., & Sande, M. A. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.4.611 · Cited by 91
Treatment of Staphylococcal Septicemia with Vancomycin
Kirby, W. M. M., Perry, D. M., & Bauer, A. W. (1960) · New England Journal of Medicine · doi:10.1056/nejm196001142620201 · Cited by 81
Je, G., Heilman, F. R., Nichols, D. R., & WELLMAN, W. E. (1958) · PubMed · Cited by 77
Vancomycin Therapy for Infective Endocarditis
GERACI, J. E., & Wilson, W. R. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.supplement.s250 · Cited by 62
Aslangul, E., Baptista, M., Fantin, B., Depardieu, F., Arthur, M., Courvalin, P. M., & Carbon, C. (1997) · The Journal of Infectious Diseases · doi:10.1093/infdis/175.3.598 · Cited by 61
Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin
Wong, S. S. Y., Ng, T. K., Yam, W.-C., et al. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00141-8 · Cited by 51
Schwaber, M. J., Wright, S. B., Carmeli, Y., Venkataraman, L., DeGirolami, P. C., Gramatikova, A., Perl, T. M., Sakoulas, G., & Gold, H. S. (2003) · Emerging infectious diseases · doi:10.3201/eid0906.030001 · Cited by 49
Nahata, M. C. (2009) · Chemotherapy · doi:10.1159/000238512 · Cited by 49
Community-acquired methicillin-resistant Staphylococcus aureus infections--Michigan.
(1981) · PubMed · Cited by 44
Vancomycin, a new antibiotic. II. In vitro antibacterial studies.
Jm, M., Rn, W., & Dw, Z. (2002) · PubMed · Cited by 42
Rybak, M. J., & Boike, S. C. (1986) · Annals of Pharmacotherapy · doi:10.1177/106002808602001003 · Cited by 39
Validation and Clinical Application of Molecular Methods for the Identification of Molds in Tissue
Paterson, P., Seaton, S., McHugh, T. D., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/498111 · Cited by 37
A critical evaluation of vancomycin for treatment of bacterial meningitis
Ahmed, A. I. (1997) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199709000-00014 · Cited by 34
Persistent staphylococcal bacteremia in an intravenous drug abuser
Barg, N. L., Supena, R. B., & Fekety, R. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.2.209 · Cited by 31
Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children.
Mp, G., Dk, B., & Jl, S. (1989) · PubMed · Cited by 31
Lefort, A., Baptista, M., Fantin, B., Depardieu, F., Arthur, M., Carbon, C., & Courvalin, P. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.476 · Cited by 27
Vancomycin; continued clinical studies.
Griffith, R. S. (2002) · PubMed · Cited by 24
Vancomycin, a new antibiotic. III. Preliminary clinical and laboratory studies.
Griffith, R. S., & Peck, F. B. (2002) · PubMed · Cited by 22
Cited by
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Self-citationAntimicrobial Resistance: a One Health Perspective
McEwen, S. A., & Collignon, P. J. (2018) · Microbiology Spectrum · doi:10.1128/microbiolspec.arba-0009-2017 · Cited by 1,199
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence
Christaki, E., Marcou, M., & Tofarides, A. (2020) · Journal of Molecular Evolution · doi:10.1007/s00239-019-09914-3 · Cited by 780
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
Metadata
- Authors
- Levine, D. P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-01-01
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S5-S12
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2056026648
- Cited by
- 838
- References
- 79
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.